Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company G2B Pharma Inc.
DescriptionNasal spray formulation of epinephrine using Shin Nippon's uco System nasal delivery platform
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Inflammation (unspecified)
Indication DetailsTreat anaphylaxis
Regulatory Designation
PartnerShin Nippon Biomedical Laboratories Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today